Literature DB >> 12377660

Successful treatment of extracranially metastasized pineal gland germinoma with high-dose methotrexate.

T Fietz1, E Thiel, C Baldus, I W Blau, G Stoltenburg, W U Knauf.   

Abstract

Germinoma of the pineal gland is a rare disease usually confined to the brain which responds well to radiotherapy. Spinal seeding occurs in approximately 4% of cases and distant metastases are extremely rare. We report on a 27-year-old female with an intracranially metastasized pineal gland germinoma, meningeal carcinomatosis and distant bone metastases. Treatment was initiated with intrathecal methotrexate (MTX) and continued with high-dose intravenous MTX. The therapy was very well tolerated apart from reversible hepatic toxicity requiring a dose reduction. The patient was in complete remission after three courses followed by two consolidation cycles; the patient has now been in continuous complete remission for more than 22 months. This is the first report to show that MTX is a potent drug in treating pineal gland germinoma. Long-term side effects of radiotherapy such as reduced mental function or hypopituitarism can probably be avoided. Single-agent high-dose MTX may provide high efficacy with limited adverse effects, especially at a more advanced tumor stage with spinal seeding and extracranial disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377660     DOI: 10.1093/annonc/mdf276

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  2 in total

Review 1.  Primary spinal yolk sac tumor with brain metastasis: case report and review of the literature.

Authors:  Peter Kan; Oren N Gottfried; Deborah T Blumenthal; James K Liu; Karen L Salzman; Jeannette Townsend; Randy L Jensen
Journal:  J Neurooncol       Date:  2006-07       Impact factor: 4.130

2.  Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors.

Authors:  Nobusada Shinoura; Yusuke Tabei; Ryozi Yamada; Kuniaki Saito; Masamichi Takahashi
Journal:  J Neurooncol       Date:  2007-12-12       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.